Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective

In this downloadable slideset, Ghassan K. Abou-Alfa, MD, MBA, reviews the rationale for immunotherapy in hepatocellular carcinoma, as well as the emerging and ongoing data supporting the use of immune checkpoint inhibitors to treat patients with HCC, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting.

In this downloadable slideset, Osama E. Rahma, MD, provides an overview of immunotherapy in cancer, including tumor immunology and evolution of immune checkpoint inhibitors in solid tumors, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting.

In this downloadable slideset, Andrew X. Zhu, MD, PhD, FACP, reviews the key issues around integrating immune checkpoint inhibitors into the clinic for patients with HCC, including management of immune-related adverse events, predictors of response, resistance, and safety concerns, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting.

Review the mechanism of action for immune checkpoint inhibitors, the rationale and data supporting their use in HCC, and key issues and controversies around moving this new class of agents into the clinic from the live satellite symposium at AASLD 2016.

Ghassan K. Abou-Alfa, MD, MBA Osama E. Rahma, MD Tamar Taddei, MD Andrew X. Zhu, MD, PhD, FACP Released: December 5, 2016